

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

16

of

16

Complete if Known

Application Number

10/010942

Filing Date

December 6, 2001

First Named Inventor

Basi, Guriq et al.

Group Art Unit

1645

Examiner Name

Attorney Docket Number

ELN-002

KAB	B1	Du Y, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001 Sep 11;57(5):801-5.	
KAB	B2	Small DM, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001 Aug;2(8):595-8	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
KAB	B3	US 2001/0102261	A1	Raso	08-01-2002	
KAB	B4	US 2002/0136718	A1	Raso	09-26-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
KAB	B5		WO 00/77178	A1		12-21-2000		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
KAB	B6	09/724,842		Chaffour et al.	N/A	

Examiner Signature

/Kimberly Ballard/

Date Considered

05/16/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a checkmark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23

Substitute for form 1449A/B/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/010,942	
			Filing Date	December 6, 2001	
			First Named Inventor	Basi, Gurig	
			Art Unit	1647	
			Examiner Name	Christopher J. Nichols	
Sheet	2	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number+Kind Code ² (If known)			
KAB	340	2002/0162129 A1	10-31-2002	Lannfelt	
✓	342	2002/0009445 A1	01-24-2002	Du, et al.	
✓	345	2002/0077288 A1	06-21-2004	Frangione 2852	
KAB	346	5,935,927	08-10-1999	Vitek, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² +Number ² +Kind Code ² (If known)				
KAB	341	WO 02/03911 A2	01-17-2002	Lannfelt, L.		
KAB	343	EP 1172378 A1	01-16-2002	Dodel, Dr. R., et al.		
KAB	344	WO 01/80182 A2	11-29-2001	University of New York		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ³
KAB 	335	Masliah, et al. "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease." <i>PNAS</i> . 2001; 98(21):12245-50.				
	336	Perutz, et al. "Amyloid fibers are water-filled nanotubes." <i>PNAS</i> . 2002; 99(8):5591-5.				
	337	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era." <i>Trends In Biotech.</i> 2000; 18(1):34-9.				
	338	Stein, et al. "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways." <i>The Journal of Neuroscience</i> . 2002 Sep 1; 22(17):7380-8.				
	339	Tennent, et al. "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis." <i>PNAS</i> . 1995; 92:4299-303.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--